Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceuticals with a different idea entirely: skip the vaccine and deliver the antibody directly.

In Vivo's David Wild talks to Tonix CEO Seth Lederman about TNX-4800, a fully human monoclonal antibody targeting OspA on the Lyme-causing bacterium Borrelia burgdorferi. Lederman explains why the unusual biology of OspA makes it better suited to a monoclonal approach than a traditional vaccine, how the antibody works inside the tick's midgut to kill the bacteria and block their migration before they can enter a human host, and what the Phase I data tell us about safety, dosing, and the planned two-dose seasonal regimen. He also discusses the adaptive Phase II field study Tonix is preparing for 2027, the lessons (and the lack of information) from the Valor trial, and the long-term questions around who would use this product, how it would be reimbursed, and whether the health economic case can be made for a seasonal preventive in a disease whose chronic form remains medically and politically contested.

This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who consulted on the launch and conducted interviews with physicians, nurses, and hospital administrators before and after it, and is managing partner of Litmys, a life sciences commercial strategy consulting firm; Diane Parks, who led the Yescarta launch for Kite; and Jim Haag, a patient who received CAR-T therapy. It's a candid, unfiltered look at the gap between what innovation promises and what the healthcare system actually delivers.

Here are some of Harris Kaplan’s contributed articles for In Vivo:

Commercialization 3.0: Achieving New Product Success In Health Care’s New Era

Commercialization 3.0: Recognizing And Managing The Human Side Of Change

Physician Behavioral Inertia: Innovation’s Greatest Enemy

AI, Philips, Healthtech, Future Health Index 2026

GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to predict a drug candidate’s safety, efficacy, and off‑target risks before the first patient is enrolled. They discuss how GATC’s Operon platform underpins Derisq and the company’s own pipeline, why a Lloyd’s of London syndicate is using the tool to underwrite clinical‑trial insurance, and how investors are leaning on these models to decide which programs to back.

A conversation with Jeremy Levin — physician-scientist, former Teva CEO, and author of Biotech and the Balance — on why America's biotech industry is at a strategic inflection point. Levin examines the forces undermining innovation: short-term capital structures mismatched to drug development timelines, eroding public trust in science and vaccines, and the hollowing out of NIH, FDA, and CDC. He outlines what bold leadership looks like in practice — defending facts, engaging patients, and treating biotech as national infrastructure before it's too late.

Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine.

Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that has long constrained European biotech's ability to build at US scale.

Tags: Venture capital, European biotech, Fundraising, Exits, Early-stage investment

Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast) is reshaping care in chronic inflammatory skin diseases, why Arcutis is pushing beyond dermatology offices into primary care and pediatrics, and how new assets like ARQ‑234 fit into the company’s long‑term growth strategy. The conversation also covers leadership lessons from Watanabe’s time in the US Navy Reserves, his practice of speaking directly with frontline employees and his perspective on capital markets and policy decisions that will shape the future of dermatology innovation.